Continued progress on XF-73 partnering discussions
Susan Koppy appointed to drive business development activities
$2bn XF-73 Nasal market opportunity
Brighton, United Kingdom – 29th June 2023: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections, today provides an update on the progress made on business development and partnering activities relating to XF-73 Nasal, its lead asset, and a market research report which is being undertaken to confirm the market potential for this asset. In addition, the Company today provides an update on the progress made in its search for a new CEO.